This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Aimovig
  • /
  • Study to Evaluate the Efficacy and Safety of Erenu...
Clinical trial

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention (ARISE)

Read time: 1 mins
Last updated:11th Oct 2022
Identifier: NCT02483585
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention (ARISE)


Brief Summary:

To evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days, in adults with episodic migraine.

Detailed Description:
Adults with a history of migraine with or without aura for ≥ 12 months and who experience ≥ 4 to < 15 migraine days per month with < 15 headache days per month will be randomized 1:1 to placebo or erenumab. Double-blind erenumab or placebo will be administered during the 12-week double-blind treatment phase and open-label erenumab will be administered during the 28-week open-label treatment phase.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 577 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
Actual Study Start Date: July 19, 2015
Actual Primary Completion Date: July 11, 2016
Actual Study Completion Date: March 20, 2017

Arm:
- Placebo Comparator:
Placebo
- Experimental: Erenumab

Category Value
Study type(s) Interventional
Expected enrolment 577
Study start date 19 July 2015
Estimated primary completion date 20 March 2017

View full details